There’s been a lot of hype around new Hep C drugs (cough, Gilead, cough), but less attention’s paid to Hepatitis B, a stunningly prevalent version of the virus that can lead to cirrhosis and liver cancer.
Novira Therapeutics just raised $9 million in debt from 10 investors, according to a regulatory filing. The startup last year raised a $25 million Series A, with investors that included Versant Ventures, 5AM Ventures and Canaan Partners.
The company’s NVR 3-778 antiviral is a small molecule drug that inhibits the Hep B core or capsid protein. It recently released Phase 1b trial info, which showed that Novira’s lead candidate was well-tolerated in 40 subjects.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
About one third of the world’s population is infected with Hep B, according to the World Health Organization; about 5 percent have a chronic form of the disease. The infection leads to more than 1 million deaths per year, the WHO says.